CLINICAL_TRIALS ClinicalTrials.gov record update

A Real World, Prospective, Single-center, Observational Study Comparing Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab or Natalizumab

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04837651
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:05.044634+00:00
Published At: 2021-08-02T00:00:00+00:00
Record Updated At: 2021-08-02
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Multiple Sclerosis", "Demyelinating Autoimmune Diseases, CNS", "Autoimmune Diseases of the Nervous System", "Nervous System Diseases", "Demyelinating Diseases", "Autoimmune Diseases", "Immune System Diseases", "Pathologic Processes"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2021-08-02"
protocolSection.identificationModule.nctId: "NCT04837651"
protocolSection.identificationModule.officialTitle: "A Real World, Prospective, Single-center, Observational Study Comparing Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab or Natalizumab"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: []
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.